tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Organogenesis Amends Credit Agreement Amid Revenue Decline

Story Highlights
Organogenesis Amends Credit Agreement Amid Revenue Decline

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Organogenesis Holdings ( (ORGO) ) is now available.

On August 5, 2025, Organogenesis Holdings Inc. amended its Credit Agreement to adjust financial covenants and accommodate its fiscal needs. The company reported a decrease in net product revenue to $100.8 million for the second quarter of 2025, compared to $130.2 million in the same period of 2024, with a net loss of $9.4 million, indicating a challenging financial period.

The most recent analyst rating on (ORGO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.

Spark’s Take on ORGO Stock

According to Spark, TipRanks’ AI Analyst, ORGO is a Neutral.

The overall stock score of 57.8 reflects significant financial challenges with declining revenue and profitability. However, strong technical momentum and strategic initiatives outlined in the earnings call provide a basis for cautious optimism. Poor valuation metrics underscore the need for careful consideration.

To see Spark’s full report on ORGO stock, click here.

More about Organogenesis Holdings

Organogenesis Holdings Inc. is a leading regenerative medicine company that develops, manufactures, and commercializes product solutions primarily for the Advanced Wound Care and Surgical & Sports Medicine markets.

Average Trading Volume: 1,147,848

Technical Sentiment Signal: Buy

Current Market Cap: $574.6M

For an in-depth examination of ORGO stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1